BioLife Solutions, a Washington-based life sciences and cell-gene therapy tool developer, has drawn significant takeover interest from multiple buyers, including bioprocessing diagnostics company Repligen Corporation. The news has led to a nearly 8% surge in BioLife's stock.
Multiple entities are eyeing BioLife Solutions, with Repligen identified as one of the key suitors looking to expand its footprint in the cell and gene therapy market.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.